PCOS Has a New Name. What PMOS Reveals About Your Fertility

If you've been diagnosed with PCOS, something changed in May 2026 — and most of your healthcare team may not have mentioned it yet.

The condition now has a new name: PMOS, short for Polyendocrine Metabolic Ovarian Syndrome. The rename wasn't cosmetic. It reflects a fundamental correction in how medicine understands a condition that affects an estimated 8 to 13 percent of reproductive-age women worldwide, according to the international consensus published in The Lancet.

Understanding what's behind the name change — and what it reveals — matters for how you approach fertility planning, whether you're trying to conceive naturally, preparing for IVF, or exploring other paths to parenthood.

The Surprising Reason the Name Needed to Change

The name "Polycystic Ovary Syndrome" was built around a visual finding on ultrasound — small, fluid-filled structures on the ovaries. The problem: those structures are not cysts. They are healthy, immature antral follicles — egg-containing sacs whose development has paused due to hormonal imbalances. They carry no direct danger on their own.

Calling them cysts wasn't just imprecise. It caused real harm. Patients received alarming diagnoses framed around structures that didn't warrant alarm. Others spent years — sometimes decades — treating PCOS as a purely reproductive issue, missing the metabolic management that should have started at diagnosis.

The new name — PMOS — is built around what the condition actually is. Polyendocrine reflects that it spans multiple interacting hormone systems, not just the reproductive axis. Metabolic names the central dysfunction that drives many of its downstream effects. Ovarian retains the reproductive dimension without making it the defining one.

Insulin Resistance: The Engine Behind PMOS Most Patients Miss

Insulin resistance is common in PMOS and central to the 2026 international consensus framing. That shift reframes how the condition should be understood — and managed.

When cells resist insulin's signals, the pancreas compensates by producing more of it. Elevated insulin then stimulates the ovaries to produce androgens — male-type hormones. High androgens disrupt the normal follicle development cycle, interfering with ovulation and contributing to the symptoms many patients with PMOS recognize: irregular periods, excess facial or body hair, acne, and weight patterns that resist standard interventions.

This is not a willpower problem. It is a hormonal cascade with a root that begins outside the ovaries.

From a fertility standpoint, managing insulin resistance before trying to conceive is an important topic to discuss with a reproductive endocrinologist. Yet under the old PCOS framework, metabolic preparation was often deprioritized in favor of ovulation induction alone. The PMOS rename is, in part, a signal to clinicians: consider metabolic screening and preparation alongside ovulation-focused treatment. For a clinician-level overview, the Endocrine Society's PCOS resource library remains current.

What "Polyendocrine" Means for Your Whole Body — Not Just Your Ovaries

The "polyendocrine" part of PMOS points to a reality that clinical guidelines from both ASRM and ESHRE have emphasized for years: this condition involves several interacting hormone systems simultaneously, and treating it as a single-organ problem misses the bigger picture.

The reproductive axis — FSH, LH, estrogen, and progesterone — is dysregulated. So is the metabolic axis: insulin, cortisol, and often thyroid function. Androgen levels are elevated. The interplay between these systems makes PMOS difficult to manage with any single-target treatment and explains why the most effective approaches address insulin and androgen levels alongside ovulatory function.

For someone planning a pregnancy, this has a practical implication. Getting a full endocrine and metabolic workup — not just a reproductive hormone panel — gives a clearer starting point. That workup may include an oral glucose tolerance test (OGTT), a lipid panel, blood pressure assessment, and thyroid screening, in addition to AMH and antral follicle count. If your current provider has not ordered these, it is reasonable to ask.

PMOS and Egg Quality: The Real Story

A common fear after a PMOS diagnosis is that egg quality will be poor. The reality is more nuanced — and for many patients, more encouraging than they expect.

People with PMOS often have a high ovarian reserve, reflected in elevated AMH levels and a larger-than-average antral follicle count. During IVF, this can mean a stronger ovarian response than expected, but response varies widely by age, medication protocol, metabolic health, and individual ovarian biology. A higher egg count does not automatically mean higher embryo quality or a better outcome.

The challenge lies in egg maturation. Hyperandrogenism — elevated androgen levels — can interfere with the final stages of follicle development. Insulin resistance adds another layer: it may impair mitochondrial energy production inside developing eggs and allow metabolic byproducts called advanced glycation end-products (AGEs) to accumulate in follicular fluid. Chronic low-grade inflammation, common in PMOS, creates additional oxidative stress in the follicular environment.

None of this is fixed or inevitable. Targeted preparation in the weeks before a stimulation cycle may help optimize the metabolic environment in which eggs mature — which is what the next section addresses.

The 90-Day Metabolic Priming Protocol Before IVF

One of the most actionable implications of the PMOS framework is discussing a structured preparation period before beginning a stimulation cycle. For some patients, the goal is to improve insulin sensitivity, lower androgen levels, and reduce systemic inflammation before the ovaries are asked to respond to medications.

What this window typically involves:

• Metformin — started 8 to 12 weeks before the IVF cycle, where appropriate, to improve insulin sensitivity and reduce systemic inflammation. Your reproductive endocrinologist will determine if this is suitable for your situation.
• Low glycemic index diet — reducing blood sugar spikes helps moderate the androgen-insulin feedback loop that drives many PMOS symptoms.
• Resistance training — building lean muscle increases insulin sensitivity through mechanisms independent of weight loss, making it valuable even when the scale doesn't move.
• Folate supplementation — at standard preconception doses, or higher if BMI is elevated, per current guidelines.
• Sleep and cortisol management — chronic elevated cortisol worsens insulin resistance. This is worth addressing before, not after, a treatment cycle begins.

For those pursuing ovulation induction rather than IVF, Letrozole is now the recommended first-line pharmacological treatment for PMOS-related anovulatory cycles, based on current international consensus guidelines. This replaces older protocols that defaulted to Clomiphene as the starting point.

OHSS: The IVF Risk That's Highest in PMOS Patients (and How to Prevent It)

Ovarian Hyperstimulation Syndrome (OHSS) is the most significant safety concern for PMOS patients undergoing IVF. Because PMOS ovaries are highly responsive to stimulation medications, there is a meaningful risk of recruiting too many follicles, leading to ovarian swelling, fluid shifts into the abdomen, and in severe cases, complications that may require hospitalization.

The good news is that OHSS risk can often be reduced with careful protocol selection and monitoring. Current guidance outlined in the ASRM guideline on prevention and treatment of moderate and severe OHSS points to three key strategies:

• GnRH antagonist protocol — commonly considered for patients at higher OHSS risk. It allows flexible control over follicular recruitment and can be adjusted mid-cycle based on ovarian response.
• GnRH agonist trigger — replacing the traditional hCG trigger for final egg maturation in selected patients. This can reduce the risk of severe OHSS.
• Freeze-all strategy — rather than transferring an embryo in the same cycle, viable blastocysts are vitrified and transfer is scheduled for a later cycle. This may reduce late-onset OHSS risk and allows the uterine lining to be prepared separately.

The ESHRE 2023 guideline emphasizes individualized protocol selection, OHSS prevention, and careful counseling rather than one universal IVF approach for every patient with PMOS. If your IVF clinic has not discussed these specific approaches, it is worth raising them directly.

From IVF to Donor Eggs: When to Have the Conversation

Most people with PMOS pursue pregnancy with their own eggs, and many succeed with appropriate protocols. But when multiple cycles result in few viable blastocysts, poor embryo development, or recurrent implantation failures despite high-quality embryos, the conversation about donor eggs becomes relevant.

Using donor eggs is not a last resort. It is a different clinical path — and for some patients, a more appropriate one after specialist review. Donor egg outcomes are often less dependent on the intended parent's age than own-egg IVF because egg age is a major factor in embryo development, but outcomes still vary by donor, embryo quality, uterine factors, clinic protocols, and transfer history. The CDC ART Success Rates database and SART national reports are useful starting points for understanding how clinics report donor-egg outcomes.

Questions worth raising with your reproductive endocrinologist before making this decision:

• How many of my retrieved eggs reached the blastocyst stage, and what were their grades?
• Were chromosomal abnormalities from PGD testing consistent, or did they vary across cycles?
• What would my prognosis look like with donor eggs, given my age and history?
• At what point would you recommend considering donor eggs over another stimulation cycle?

Reproductive psychologists often suggest setting these parameters in advance — deciding with your partner and care team how many cycles you will attempt before pivoting — rather than making that call in the exhaustion of a failed cycle. Our guide on when to consider stopping IVF addresses this transition in more detail.

If donor eggs are paired with a gestational carrier, reviewing a dedicated donor egg surrogacy program and using a surrogacy cost calculator can help you understand what an international program typically involves financially.

Pregnancy with PMOS: Monitoring Matters More Than You Think

For those who carry a pregnancy with PMOS — through natural conception, IVF, or donor eggs — ongoing monitoring is important. PMOS is associated with elevated risks for gestational diabetes, preeclampsia, and cardiovascular complications during delivery. These risks are manageable with appropriate prenatal care, but they are best addressed proactively.

An early glucose tolerance test, consistent blood pressure monitoring beginning in the second trimester, and a maternal-fetal medicine consultation are reasonable topics to raise at the start of prenatal care.

In rare cases, pre-existing PMOS-related conditions — severe uncontrolled hypertension, advanced diabetic nephropathy, or cardiomyopathy — may make carrying a pregnancy medically inadvisable. Recurrent, unexplained implantation failures despite high-quality embryos can also point toward a gestational carrier as a clinical consideration. If this is your situation, understanding how gestational surrogacy works and how long the process takes is a useful starting point.

The Mental Health Dimension: Depression, Body Image, and Fertility Grief

PMOS can carry a psychological burden that clinical frameworks have historically underserved. The international PCOS guideline recognizes depression, anxiety, eating disorders, and body image concerns as important parts of care. RESOLVE: The National Infertility Association also offers patient-facing support for people navigating PCOS, infertility, and treatment decisions.

The physical symptoms of PMOS — changes in weight, skin, and hair — affect how patients relate to their bodies in ways that clinical appointments rarely have time to address. The fertility challenges add another layer. When IVF cycles fail, or when the question of donor eggs or a gestational carrier enters the picture, many patients describe something close to grief: for the conception they had imagined, for the genetic connection they may not have, for the path they had planned.

That grief is valid. Naming it matters.

Cognitive behavioral therapy (CBT), counseling, and peer support can be appropriate parts of care when mood, body image, or fertility grief are affecting daily life. Stress management is not a substitute for medical treatment, but it can support the broader metabolic and emotional work that PMOS care often requires.

If your current care team does not engage with the psychological dimension of your diagnosis, it is worth raising. A reproductive psychologist or licensed counselor with fertility experience is a legitimate, evidence-supported part of a complete treatment plan.

When Gestational Surrogacy Becomes Part of the Conversation

For a small number of people with PMOS — those with serious medical contraindications to pregnancy, or those who have experienced repeated implantation failures despite excellent embryo quality — gestational surrogacy becomes a medically grounded path to parenthood. This decision should come after review with a reproductive endocrinologist, maternal-fetal medicine specialist when relevant, and qualified legal counsel.

Surrogacy is not the right step for most people with PMOS. If carrying a pregnancy has become medically unsafe or donor eggs plus a gestational carrier are being discussed, compare the available international surrogacy program paths, including own-oocyte surrogacy and donor egg surrogacy, before making a decision.

Related reading

• How Gestational Surrogacy Works
• Donor Egg Surrogacy
• Own-Oocyte Surrogacy
• When to Consider Stopping IVF
• Surrogacy Cost Calculator